The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic

The stem cell-derived therapy at the center of Vertex’s $950 million buyout of Semma Therapeutics in 2019, one that features prominently in the company’s overall cell and gene therapy push, is one step closer to reaching the clinic.